Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Back to basics: luring industry back into neuroscience

Nature Neuroscience volume 19, pages 1383–1384 (2016)Cite this article

Subjects

To the Editor:

Industry has retreated from investment in brain disorders due to high failure rates in clinical trials. With new successes in genetics, however, there are early hints of renewed interest, especially for rare monogenic disorders. What would accelerate re-engagement with brain disorders? A new embrace of basic studies of disease mechanism—a key missing element of success—and eschewal of putative animal models of disease that have proven a distraction may help.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bunnage, M.E. Nat. Chem. Biol. 7, 335–339 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Pankevich, D.E., Altevogt, B.M., Dunlop, J., Gage, F.H. & Hyman, S.E. Neuron 84, 546–553 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hyman, S.E. Sci. Transl. Med. 4, 155cm11 (2012).

    PubMed  Google Scholar 

  4. Institute of Medicine. Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary. (National Academies Press, Washington, DC, 2013).

  5. Institute of Medicine. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. (National Academies Press, Washington, DC, 2013).

  6. Nestler, E.J. & Hyman, S.E. Nat. Neurosci. 13, 1161–1169 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sittig, L.J. et al. Neuron 91, 1253–1259 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sullivan, P.F., Daly, M.J. & O'Donovan, M. Nat. Rev. Genet. 13, 537–551 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Doan, R.N., Bae, B.-I., Cubelos, B., Chang, C. et al. Mutations in human accelerated regions disrupt cognition and social behavior. Cell http://dx.doi.org/10.1016/j.cell.2016.08.071 (2016)

Download references

Author information

Authors and Affiliations

  1. Steven E. Hyman is in the Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA,

    Steven E Hyman

  2. the Stanley Center, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.,

    Steven E Hyman

Authors
  1. Steven E Hyman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hyman, S. Back to basics: luring industry back into neuroscience. Nat Neurosci 19, 1383–1384 (2016). https://doi.org/10.1038/nn.4429

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nn.4429

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research